Capricor Therapeutics Faces Securities Fraud Class Action

The litigation centers on claims that Capricor Therapeutics failed to disclose critical information concerning its clinical data analysis for Deramiocel, a treatment for Duchenne muscular dystrophy. According to the complaint filed by Glancy Prongay Wolke & Rotter LLP, the company modified its pre-specified statistical analysis plan without prior FDA agreement before resubmitting its Biologics License Application. Plaintiffs argue these omissions created a substantial risk that the FDA would reject the drug’s effectiveness, rendering the company’s public statements about its business prospects materially misleading.

Shareholders who purchased securities during the specified window retain the right to participate in the litigation or remain absent class members, as no class has yet been certified. Those seeking to serve as lead plaintiff must file a motion with the court by the September 28 deadline. Glancy Prongay Wolke & Rotter LLP, a firm noted for its work in investor recoveries, is currently representing potential claimants in the action.